Groningen, The Netherlands – 01 December, 2024 – InnoCore Pharmaceuticals, a Dutch biopharmaceutical drug delivery and development company, today announced that it has been awarded a grant from the European Union's European Regional Development Fund (ERDF) for is participation in the BBubbleCaRD project. BBubbleCaRD (Bioresorbable Bubbles for Controlled Release of Drugs) aims to revolutionize targeted drug delivery across the blood-brain barrier (BBB) to improve the treatment of serious brain-related disorders.
In the Netherlands, approximately 150,000 people are diagnosed with a brain disorder each year, including neurodegenerative disorders such as Parkinson's and Alzheimer's disease, multiple sclerosis and brain tumors. Brain tumors, with an incidence of 1,400 new cases annually, are among the most challenging malignancies to treat. The prognosis for brain tumors, particularly glioblastoma, remains poor, with a two-year survival rate of less than 20%. The urgency for new treatment options for brain tumors is very high.
Within BBubbleCaRD InnoCore will closely collaborate with Bether Encapsulates, Solstice Pharmaceuticals and the research group of prof. dr. Patrick van Rijn at the Department of Biomaterials & Biomedical Technology of the University Medical Center Groningen (UMCG). With the financial support of the European Union's European Regional Development Fund (ERDF), the Dutch Ministry of Economic Affairs, and the Groningen Municipality, and awarded by 'Samenwerkingsverband Noord-Nederland' (SNN), the partners will develop bioresorbable antibubbles for ultrasound-triggered intravenous delivery of anti-cancer medication across the blood-brain barrier. Antibubbles are gas bubbles with a stabilizing shell of nanoparticles. Drugs encapsulated in the antibubbles are released when the bubble bursts under the influence of medical ultrasound. Antibubbles have already shown promising results in animal studies. By joining forces, the BBubbleCaRD consortium aims to advance antibubbles-based ultrasound-triggered drug delivery towards human clinical application for more effective treatment of brain cancers.
About InnoCore Pharmaceuticals
InnoCore Pharmaceuticals is a pharmaceutical drug delivery and development company focused on the development and clinical manufacturing of injectable sustained release drug delivery products for the treatment of chronic and site-specific diseases. Utilizing its proprietary SynBiosys® and InGell® biodegradable polymeric drug delivery platforms, InnoCore develops long-acting injectable depots in the form of microparticles, implants and gels for precisely controlled delivery of therapeutic compounds, including small molecules, peptides and proteins. Over the years, InnoCore's versatile drug delivery platforms have shown their safety and effectiveness in several pre-clinical and clinical trials. Since its inception in 2004, InnoCore has successfully established partnerships with biomedical, biotech and pharmaceutical companies. In 2013, the first product with InnoCore's SynBiosys® drug delivery technology incorporated received regulatory approval and is now available in the market. InnoCore Pharmaceuticals is privately owned and located in Groningen, The Netherlands. For more information visit www.innocorepharma.com
Go back to news